Amarin Corp Plc (AMRN)

[sharinky]

Vascepa has efficacy and safety including a 7 year track record of being on the market. It will be approved. You are not missing anything.

·
A little conversation from twitter last night -

Sep 9
Citi positive comments $AMRN Biotech Conference Takeaways — hosted two cardiologists at conference. Potential Market for Vascepa is Very Large – Both agreed that REDUCE-IT was one of the more important clinical trials in years and that results of this magnitude can’t be ignored.


dough
@semodough
KOLs indicated “millions and millions” of people could benefit from Vascepa. When we asked what percentage of patients on statins should also be on Vascepa, one doc indicated ~1/4 and our other doc suggested ~1/3.


16h
Replying to
@semodough
If you calculate based on those indications:

- 38M on statins (US) per $amrn presentation
- 1/3=12,7M; 1/4=9,5M
- mean = 11M x 1625 USD/y = 18B USD/year
- 18B x 3 = 54B mcap = 164 USD/share

Can this be realistic?